Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma Clinical research trials and Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma. Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma clinical trial. Human subjects often get the best healthcare possible for their Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "C" Clinical Trials Conditions > Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma

Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma



Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma

For Condition: Mixed Gliomas,adult ependymoma,adult glioblastoma multiforme,adult anaplastic astrocytoma,adult anaplastic oligodendroglioma
Status: No longer recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy following radiation therapy in treating patients who have malignant glioma.
Details: OBJECTIVES: - Determine the safety and efficacy of extended low-dose temozolomide when combined with carmustine after radiotherapy in patients with malignant glioma. - Determine the maximum tolerated dose of this combination in this patient population. - Determine time to progression as measured from baseline gadolinium-enhanced magnetic resonance imaging in patients treated with this regimen. OUTLINE: This is a dose-escalation study of temozolomide. Patients receive oral temozolomide once daily on days 1-28 and carmustine IV over 1-3 hours beginning within 72 hours after starting temozolomide. Courses repeat every 8 weeks for up to 1 year in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 2 months. PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study within 1-2 years.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed malignant glioma - Glioblastoma - Gliosarcoma - High-grade glioma - Anaplastic astrocytoma - Anaplastic mixed oligoastrocytoma - Anaplastic oligodendroglioma - Anaplastic ependymoma - Must have completed radiotherapy PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - More than 3 months Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT/SGPT less than 3 times ULN - Alkaline phosphatase less than 2 times ULN Renal: - BUN less than 1.5 times ULN - Creatinine less than 1.5 times ULN Pulmonary: - Pulmonary function test with diffusion greater than 50 OR - Clearance by the pulmonary service Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No AIDS-related illness - No nonmalignant systemic disease that would preclude study - No acute infection requiring IV antibiotics - No psychiatric condition that would preclude study compliance - No frequent vomiting or medical condition that would interfere with oral medication intake (e.g., partial bowel obstruction) - No other prior or concurrent malignancy except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior immunotherapy - No prior biologic therapy Chemotherapy: - No prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - At least 2 weeks since prior radiotherapy Surgery: - Not specified
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
JeffreyRaizer,  Study Chair,  Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center
New York City,  New York,  10021
United States
 


Additional Information:
Study ID Numbers:  CDR0000067793;  MSKCC-99114,NCI-G00-1765
Study Start Date: 
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005637

Other Adult Anaplastic Oligodendroglioma Studies:
1. Combination Chemotherapy for Patients With Brain Cancer

2. Vaccine Therapy in Treating Patients With Malignant Glioma

3. Taurolidine in Treating Patients With Recurrent or Progressive Glioma

4. Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

5. Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma

Related Studies:

Other adult anaplastic oligodendroglioma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
Modify your Search

  Other adult anaplastic oligodendroglioma Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103